Rodríguez de Castro B, Martínez-Múgica Barbosa C, Pampín Sánchez R, Fernández González B, Barbazán Vázquez F J, Aparicio Carreño C
Belén Rodríguez de Castro, Servicio de Farmacia. Hospital Universitario Cabueñes. Los Prados, 395, 33394 Gijón (Asturias). Spain.
Rev Esp Quimioter. 2020 Jun;33(3):207-211. doi: 10.37201/req/026.2020. Epub 2020 Apr 15.
Evaluation of the effectiveness of a standard dose of cefalozin 2 grams for surgical site infection (SSI) prevention in obese patients compared to non-obese patients. There is no still controversy surrounding which is the best dosage of this antibiotic in obese patients for surgical prophylaxis.
Retrospective review of men who received prophylactic cefazolin between January 1st, 2019 and June 30th, 2019 in a traumatology department of a university hospital. Patients were stratified into 2 groups: obese (≥ 100 kg and body mass index (BMI)> 30 kg / m2) and non-obese. Patients without a 90 days follow-up after surgery and/or with an active infection at the time of surgery and/or treated with immunosuppressants were excluded. Demographic data, height, real weight, smoking, diabetes, concomitant use of immunosuppressants, surgery data and presence of infection until day 90 were collected.
A total of 57 patients underwent traumatic surgery with prophylactic cefazolin, 26 non-obese and 23 obese, were studied. Both groups presented statistically significant differences in weight, BMI and post-surgery use of cefazolin. No significant differences were observed in the other variables. Two obese (8.7%) and two non-obese (7.7%) patients developed SSIs after 63 days post-surgery on average, following the difference between the groups being statistically non-significant.
This study shows that there is no significant difference in SSI with a standard prophylactic dose of two grams of cefazolin between obese and non-obese patients.
评估与非肥胖患者相比,标准剂量2克头孢洛辛预防肥胖患者手术部位感染(SSI)的有效性。对于肥胖患者进行手术预防时,这种抗生素的最佳剂量仍存在争议。
回顾性分析2019年1月1日至2019年6月30日在某大学医院创伤科接受预防性头孢唑林治疗的男性患者。患者分为两组:肥胖组(≥100 kg且体重指数(BMI)>30 kg/m²)和非肥胖组。排除术后无90天随访和/或手术时存在活动性感染和/或接受免疫抑制剂治疗的患者。收集人口统计学数据、身高、实际体重、吸烟情况、糖尿病、免疫抑制剂的联合使用情况、手术数据以及至第90天的感染情况。
共研究了57例接受预防性头孢唑林治疗的创伤手术患者,其中26例非肥胖患者和23例肥胖患者。两组在体重、BMI和术后头孢唑林的使用方面存在统计学显著差异。在其他变量中未观察到显著差异。平均术后63天,两名肥胖患者(8.7%)和两名非肥胖患者(7.7%)发生了手术部位感染,两组之间的差异无统计学意义。
本研究表明,肥胖患者和非肥胖患者使用2克标准预防剂量头孢唑林预防手术部位感染无显著差异。